Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mifepristone Access Imperiled By Supreme Court’s Draft Decision Overturning Abortion Rights

Executive Summary

Clinicians in states that ban abortion could face criminal prosecution for providing mifepristone. Access to medical abortion ‘is not a panacea’ if the court overrules Roe v. Wade as people using the drug face risks from aggressive prosecutors, ACLU attorney says.

You may also be interested in...



Republicans Turn Their Backs On Califf

A visual comparison of Robert Califf’s US FDA Commissioner confirmation votes in 2016 and 2022.

Abortion Pill Mifepristone Will No Longer Require In-Person Pick Up, US FDA Concludes

REMS modification implemented for the duration of the pandemic will become permanent, the agency determines in response to lawsuit. FDA adds a requirement that pharmacies dispensing the drug be certified.

REMS In The Time Of COVID-19: ACLU Sues FDA Over Abortion Pill Access

Medical and advocacy groups claim FDA is requiring women to fill prescriptions for Mifeprex in person while waiving REMS requirement for in-person visits for other drugs.

Related Content

UsernamePublicRestriction

Register

PS146120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel